According to the research report titled ‘Global Cell Therapy Market 2022-2028’, available with MarketStudyReport, global cell therapy market is expected to reach a valuation worth USD 10,481 million by the end of 2028, achieving a CAGR of 6.3% during the forecast period.

Several technological developments in the domain of cell therapy, rising preference for regenerative medicine, increased investments by governmental bodies in cell-based research, and soaring incidences of chronic ailments are the crucial factors favoring the growth of global cell therapy market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/5042703/

Moreover, surge in clinical trials of oncology-related cell therapy, and development of healthcare infrastructure in emerging economies are further leading to industry expansion.

Besides an extensive evaluation of the market situation, the research report also enlists the constraints and bottlenecks prevailing in the business sphere, as well as the plausible alternatives that can assist investors in generating better profits.

On top of that, the study consists of an in-depth assessment of market size, key trends, competitive scenario, and sub-segmentation. It also explores the influence of the COVID-19 outbreak on the overall industry growth and economy.

As per therapy type, worldwide cell therapy industry is bifurcated into autologous and allogeneic. Based on product terrain, the marketplace is segmented into systems & software, equipment, and consumables.

Analyzing the application spectrum, the industry is divided into musculoskeletal disorders, malignancies, dermatology & wounds, cardiovascular, and others. Speaking of the end-users, the business sphere can be classified into hospitals & clinics, research institutes, and others.

Moving on, the major regional markets analyzed in the report are North America, Europe, and Asia Pacific. Details about the growth opportunities and existing trends in these geographies are entailed in the document. 

Regarding the competitive landscape, the documentation evaluates the profiles of leading players in global cell therapy industry such as Vericel Corporation, Stempeutics Research Pvt. Ltd., Smith & Nephew plc (Osiris Therapeutics, Inc.), NuVasive, Inc., Nipro Corporation, Medipost Co., Ltd., Juno Therapeutics, Inc. (Bristol Myers Squibb Co.), Dendreon Pharmaceuticals, Inc., Castle Creek Biosciences, Inc., The Takeda Pharmaceutical Company Limited, Stemedica Cell Technologies, Inc., Organogenesis Holdings, Inc., Novartis International AG, Mesoblast Limited, Kite Pharma, Inc. (Gilead Sciences, Inc.), JCR Pharmaceuticals Co., Ltd., Cells for Cells S.A., and Allogene Therapeutics, Inc.